INmune Bio, Inc. (INMB)
Automate Your Wheel Strategy on INMB
With Tiblio's Option Bot, you can configure your own wheel strategy including INMB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INMB
- Rev/Share 0.0022
- Book/Share 1.319
- PB 4.8369
- Debt/Equity 0.0117
- CurrentRatio 2.6441
- ROIC -1.0487
- MktCap 148082352.0
- FreeCF/Share -1.454
- PFCF -4.5273
- PE -3.5181
- Debt/Assets 0.0092
- DivYield 0
- ROE -1.1866
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INMB | Rodman & Renshaw | -- | Buy | -- | $23 | Jan. 28, 2025 |
| Initiation | INMB | Alliance Global Partners | -- | Buy | -- | $20 | Oct. 21, 2024 |
| Initiation | INMB | Raymond James | -- | Outperform | -- | $18 | Sept. 27, 2024 |
| Initiation | INMB | Scotiabank | -- | Sector Outperform | -- | $22 | Aug. 22, 2024 |
News
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity
Published: June 16, 2025 by: Seeking Alpha
Sentiment: Positive
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer's readout. Lead asset XPro1595's mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, mechanistic, and limited but encouraging Phase 1b data. If XPro1595 delivers positive results, it could validate a new approach in Alzheimer's and other inflammatory diseases, but the investment remains speculative due to clinical and market risks.
Read More
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.
Read More
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.
Read More
About INmune Bio, Inc. (INMB)
- IPO Date 2019-02-04
- Website https://www.inmunebio.com
- Industry Biotechnology
- CEO Dr. Raymond Joseph Tesi M.D.
- Employees 13